Oncolytics Biotech (NASDAQ:ONCY) Insider Buys $10,069.56 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) insider Thomas Charles Heineman bought 12,132 shares of Oncolytics Biotech stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of $0.83 per share, with a total value of $10,069.56. Following the purchase, the insider directly owned 282,818 shares of the company’s stock, valued at approximately $234,738.94. This represents a 4.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Oncolytics Biotech Trading Up 27.0%

Shares of ONCY stock opened at $1.06 on Monday. The firm’s 50 day moving average is $0.98 and its 200 day moving average is $1.07. The stock has a market capitalization of $112.52 million, a P/E ratio of -3.79 and a beta of 0.99. Oncolytics Biotech Inc. has a 12 month low of $0.33 and a 12 month high of $1.51.

Institutional Trading of Oncolytics Biotech

Large investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new position in shares of Oncolytics Biotech in the third quarter worth approximately $535,000. Tocqueville Asset Management L.P. bought a new position in shares of Oncolytics Biotech in the 4th quarter worth $63,000. CIBC Private Wealth Group LLC bought a new position in shares of Oncolytics Biotech in the 4th quarter worth $44,000. Ground Swell Capital LLC purchased a new stake in shares of Oncolytics Biotech during the 4th quarter valued at $30,000. Finally, Seeds Investor LLC raised its position in shares of Oncolytics Biotech by 17.8% during the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after buying an additional 33,826 shares in the last quarter. Institutional investors own 6.82% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. HC Wainwright raised their target price on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Oncolytics Biotech currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Key Stories Impacting Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.